TY - JOUR
T1 - Pharmacogenetics in Latin American populations
T2 - Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
AU - Rodeiro, Idania
AU - Remírez-Figueredo, Diadelis
AU - García-Mesa, Milagros
AU - Dorado, Pedro
AU - Llerena, Adrián
AU - Moya, Graciela E.
AU - Ferrero, Verónica
AU - Tarazona-Santos, Eduardo
AU - Fiedler, Jenny
AU - Herrera, Luisa
AU - Rojas-Ponce, Romina
AU - Sarmiento-Sánchez, Alba P.
AU - Borbón-Orejuela, Angélica
AU - Barrantes, Ramiro
AU - Jiménez-Arce, Gerardo
AU - Céspedes, Carolina
AU - Álvarez, Mayra
AU - Pérez, Bárbaro
AU - Calzadilla, Luis
AU - Delgado, René
AU - Remirez, Diadelis
AU - Terán, Enrique
AU - Heras, Natalia
AU - Beltrán, Leonardo
AU - Hernández, Francisco
AU - Doredo, Pedro
AU - Peñas-Lledó, Eva M.
AU - Cobaleda, Jesús
AU - González-Naranjo, M. Eugenia
AU - De Andrés, Fernando
AU - Ortiz-López, Rocío
AU - Rojas-Martínez, Augusto
AU - Garza-Ocañas, Lourdes
AU - Pérez-Páramo, Yadira X.
AU - López-López, Marisol
AU - Ortega-Vázquez, Alberto
AU - Alonso-Vilatela, Elisa
AU - Monroy-Jaramillo, Nancy
AU - Vázquez, Teresa Corona
AU - Yescas-Gómez, Petra
AU - Ochoa-Morales, Adriana
AU - Sosa-Macías, Martha G.
AU - Galaviz-Hernández, Carlos
AU - Lares, Ismael
AU - Lazalde, Blanca
AU - Ramirez-Roa, Ronald
AU - Grazina, Manuela
AU - Estévez-Carrizo, Francisco E.
AU - González-Vacarezza, Nicolás
N1 - Funding Information:
AEXCID Cooperaci ó n Extreme ñ a, Junta de Extremadura (11/A002). The studies in Spain were supported by the Plan Nacional de Investigaci ó n Cient í fica, Desarrollo e Innovaci ó n Tecnológica (I + D + i) and Fondo Social Europeo of the European Union (FEDER), Instituto de Salud Carlos III-FIS (PI10/02758 to ALL, and CP06/0030 to PD). The collaboration of E.M. Pe ñ as-LLed ó PhD is gratefully acknowledged.
PY - 2012/3/1
Y1 - 2012/3/1
N2 - Meeting report of the " Second Symposium on Pharmacology of Cytochrome P450 and Transporters " organized by the Cuban Society of Pharmacology in collaboration with the European Society of Pharmacogenetics and Theranostics (ESPT) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (www.ribef.com). The Symposium covered different topics on pharmacogenetics and its clinical implications, focusing on Latin-American populations. The activities of the ESPT were also presented and discussed. The topics addressed were regulatory aspects, the use of pharmacogenetics in pre-clinical research, herbal medicine, and natural products, ending with a discussion about translation into clinical practice, specifically for cardiovascular disorders and psychiatry. Finally, the implication for population diversity in Latin America was also discussed. The RIBEF initiative represents a promising step towards the inclusion of Latin American populations among those to benefit from the implementation of pharmacogenetics in clinical practice. Among current RIBEF activities, the CEIBA.FP Consortium aims to study the variability of pheno-and genotypes in Hispanics that are relevant to pharmacogenetics. For this purpose, populations from Mexico, Cuba, Nicaragua, Costa Rica, Ecuador, Colombia, Brasil, Perú, Chile, Uruguay, Argentina, Portugal, and Spain are currently being studied. The meeting's main conclusion was that population pharmacogenetic studies as well as academic clinical trials might need to be conducted in the different geographic locations/countries. This is important in order to improve drug safety, dosage recommendations, and pharmacovigilance programs, because environmental and ethnic factors vary across locations.
AB - Meeting report of the " Second Symposium on Pharmacology of Cytochrome P450 and Transporters " organized by the Cuban Society of Pharmacology in collaboration with the European Society of Pharmacogenetics and Theranostics (ESPT) and the Ibero-American Network of Pharmacogenetics and Pharmacogenomics (www.ribef.com). The Symposium covered different topics on pharmacogenetics and its clinical implications, focusing on Latin-American populations. The activities of the ESPT were also presented and discussed. The topics addressed were regulatory aspects, the use of pharmacogenetics in pre-clinical research, herbal medicine, and natural products, ending with a discussion about translation into clinical practice, specifically for cardiovascular disorders and psychiatry. Finally, the implication for population diversity in Latin America was also discussed. The RIBEF initiative represents a promising step towards the inclusion of Latin American populations among those to benefit from the implementation of pharmacogenetics in clinical practice. Among current RIBEF activities, the CEIBA.FP Consortium aims to study the variability of pheno-and genotypes in Hispanics that are relevant to pharmacogenetics. For this purpose, populations from Mexico, Cuba, Nicaragua, Costa Rica, Ecuador, Colombia, Brasil, Perú, Chile, Uruguay, Argentina, Portugal, and Spain are currently being studied. The meeting's main conclusion was that population pharmacogenetic studies as well as academic clinical trials might need to be conducted in the different geographic locations/countries. This is important in order to improve drug safety, dosage recommendations, and pharmacovigilance programs, because environmental and ethnic factors vary across locations.
KW - Hispanics
KW - Latin America
KW - cytochrome P450
KW - pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=84860531136&partnerID=8YFLogxK
U2 - 10.1515/dmdi-2012-0006
DO - 10.1515/dmdi-2012-0006
M3 - Artículo
C2 - 22718626
AN - SCOPUS:84860531136
SN - 0792-5077
VL - 27
SP - 57
EP - 60
JO - Drug Metabolism and Drug Interactions
JF - Drug Metabolism and Drug Interactions
IS - 1
ER -